ArticleFrontiers in medicine2025
Integrating clinical features, inflammatory markers, and immune profiles: a Yunke-based nomogram model for rheumatoid arthritis prognosis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retracted
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop a prognostic nomogram integrating clinical, inflammatory, and immune parameters for rheumatoid arthritis (RA) patients receiving Yunke-drug combination therapy, facilitating personalized treatment decisions. Methods: We retrospectively analyzed 304 RA patients (2010-2024) divided into training ( Results: Six independent predictors emerged: elevated rheumatoid factor (OR = 1.32, 1.08-1.62), CRP > 10 mg/L (OR = 2.14, 1.45-3.16), ≥4 swollen joints (OR = 1.87, 1.22-2.88), TNF- Conclusion: This first multifactorial nomogram for Yunke-combined therapy integrates joint assessments, serum biomarkers, cytokine profiles, and cellular immunity indicators. Demonstrated predictive accuracy (30.5% training; 29.7% validation response rates) supports its potential for therapeutic monitoring. While internally validated, multicenter studies are required to confirm generalizability. The model establishes a framework for precision RA management, with implications for dose optimization and resistance mechanism research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.